SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bryan Arnold who wrote (791)6/2/1997 11:16:00 PM
From: John Metcalf   of 6136
 
The royalties on Saquinivir are for the purpose of keeping Roche honest, and compelling them to put equal effort into selling Viracept in Europe, along with Saq. Below the surface, there is a little more: Roche and Agouron are seriously committed to a double PI therapy, as Peter Johnson noted at a conference this Winter. Johnson said the triple combo was state of the art in 1996, but in 1997, "all bets are off".

The David Ho theorem, succinctly put by a chemist friend, has been: "It's the concs!" He means that high concentrations of PI's, which bind in a lock-and-key fashion, are necessary to bind all the virus. Since Viracept increases the blood levels of Saq, these two drugs are synergistic. After Viracept approval is granted in Europe, we should get some indication of how agressively Roche will pursue this treatment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News